Abstract
A series of N-methyl-d-aspartate (NMDA) receptor-targeted MRI contrast agents has been developed, based on the known competitive NMDA antagonist, 3,4-diamino-3-cyclobutene-1,2-dione. Their use as responsive MR imaging probes has been evaluated in vitro and two contrast agents showed 170-176% enhancements in relaxation rate, following incubation with a neuronal cell line model. A derivative of the lead compound was prepared containing a biotin moiety, and both the specificity and reversibility of binding to the NMDA cell surface receptors demonstrated using confocal microscopy.
| Original language | English |
|---|---|
| Pages (from-to) | 3148-3153 |
| Number of pages | 6 |
| Journal | Chemical Science |
| Volume | 4 |
| Issue number | 8 |
| Early online date | 6 Jun 2013 |
| DOIs | |
| Publication status | Published - 1 Aug 2013 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Responsive MR-imaging probes for N-methyl-d-aspartate receptors and direct visualisation of the cell-surface receptors by optical microscopy'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver